News

Epigral Limited informed the National Stock Exchange of India Limited and BSE Limited that the trading window for equity shares will be closed for insiders, directors, promoters, designated persons, and their immediate relatives from October 1, 2026, until 48 hours after the declaration of the un-audited financial results for the second quarter and half year ended September 30, 2026.

Net profit of Epigral declined 37.93% to Rs 99.74 crore in the quarter ended June 2026 as against Rs 160.69 crore during the previous quarter ended June 2025. Sales rose 16.29% to Rs 705.36 crore in the quarter ended June 2026 as against Rs 606.54 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales705.36606.54 16 OPM %25.4126.94 - PBDT176.64148.55 19 PBT133.74107.01 25 NP99.74160.69 -38 Powered by Capital Market - Live News

Epigral announced that as part of its strategic growth and expansion initiatives, it proposes to establish a new manufacturing facility for Epoxy Resin & Formulations and Multi-Purpose Plant (MPP) at its existing facility at Dahej, Gujarat.

Epigral will hold a meeting of the Board of Directors of the Company on 27 July 2026.

Epigral announced that the 19th Annual General Meeting(AGM) of the company will be held on 8 June 2026.